Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 7/20 | 0.38 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23547437 | 0.88 | JAK3 (0.43) | JAK3BTKALDH1A1LMNAHPGD | |
| SCHEMBL27451749 | 0.88 | JAK3 (0.43) | JAK3BTKALDH1A1LMNAHPGD | |
| SCHEMBL18904853 | 0.88 | JAK3 (0.43) | JAK3BTKALDH1A1LMNAHPGD | |
| SCHEMBL18909618 | 0.88 | JAK3 (0.43) | JAK3BTKALDH1A1LMNAHPGD | |
| SCHEMBL19353252 | 0.84 | ALDH1A1 (0.51) | JAK3BTKALDH1A1LMNAMAPT | |
| SCHEMBL10283866 | 0.84 | ALDH1A1 (0.51) | JAK3BTKALDH1A1LMNAMAPT | |
| SCHEMBL10241495 | 0.84 | ALDH1A1 (0.51) | JAK3BTKALDH1A1LMNAMAPT | |
| SCHEMBL27451704 | 0.84 | ALDH1A1 (0.51) | JAK3BTKALDH1A1LMNAMAPT | |
| SCHEMBL462207 | 0.84 | ALDH1A1 (0.44) | JAK3BTKALDH1A1LMNAHPGD | |
| SCHEMBL22631089 | 0.84 | JAK3 (0.37) | CHRNB2CHRNA4JAK3BTKFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS BIOPHARMACEUTICALS, LTD. (KY) | 2019-04-11 | — | — | US | disclosed |
| WO-2017156495-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | CHRNB2 2283/4885CHRNA4 3710/4885JAK3 110/4885 |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | CHRNB2 4718/4885CHRNA4 4628/4885JAK3 447/4885 |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | ABL1, BTK, LYN | CHRNB2 2283/4885CHRNA4 3710/4885JAK3 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.